Company: PSTV
Filing Date: 2025-07-21
Form Type: DEF 14A
Source: 0001140361-25-026611
Chunk: 43

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-21
Form: DEF 14A
Chunk 43
---
,000 |     |     9,167 |     |  54,167 |
| Greg Petersen(4)               |     |      72,500 |     |     9,167 |     |  81,167 |

| (1) | Dr. Hedrick is not included in this table as he is our Chief Executive Officer and receives no extra compensation for his service as a director. The compensation received by Dr. Hedrick in his capacity as our Chief Executive Officer is set forth in the Summary Compensation Table and further described in the “Narrative Disclosures to Summary Compensation Table.” |

| (2) | Amounts in this column represent awards of restricted stock options with the aggregate grant date fair value computed in accordance with FASB ASC Topic 718. The fair value was determined in accordance with U.S. GAAP based on the closing price of our Common Stock on the applicable grant date. The vesting of these stock awards are service based and subject to continued participant as Board members. |

| (3) | The following table provides information regarding the aggregate number of option awards granted to our non-employee directors that were outstanding as of December 31, 2024: |

| Name                      |     | Option 
 Awards 
    (#) |
| Richard J. Hawkins        |     |  5,900 |
| Howard Clowes             |     |  5,900 |
| An van Es-Johansson, M.D. |     |  5,900 |
| Robert Lenk, PhD          |     |  5,900 |
| Greg Petersen             |     |  5,900 |

| (4) | Greg Petersen resigned from the Board and his committee positions on April 18, 2025. |

Mr. Guse was elected to our Board in April 2025 and did not earn any compensation during fiscal year 2024.

25

TABLE OF CONTENTS

PAY VERSUS PERFORMANCE As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation and certain financial performance of our Company. The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the Compensation Committee view the link between the Company’s performance and its NEOs pay. Pay Versus Performance Table The table below presents information on the compensation of our Chief Executive